Abstract
Objective:The main objective of the study was to assess whether Meldonium therapy at a dose of 1000 mg per day can affect the level of NR2 peptide, a product of proteolytic cleavage of N-methyl-D-aspartate receptors (NMDA), in patients who have recently had acute ischemic stroke.Design and method:A
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
